Concert Pharma (CNCE) Tops Q2 EPS by 3c
Get Alerts CNCE Hot Sheet
Join SI Premium – FREE
Concert Pharma (NASDAQ: CNCE) reported Q2 EPS of ($0.60), $0.03 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $71 thousand versus the consensus estimate of $30 thousand.
For earnings history and earnings-related data on Concert Pharma (CNCE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: RH, Estee Lauder rise; Tesla falls
- TSS, Inc. (TSSI) Reports Q4 EPS of $0.02
- P3 Health Partners Inc. (PIII) Misses Q4 EPS by 14c, reaffirms guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!